CN1922209B - 抗Αβ抗体 - Google Patents

抗Αβ抗体 Download PDF

Info

Publication number
CN1922209B
CN1922209B CN2005800056858A CN200580005685A CN1922209B CN 1922209 B CN1922209 B CN 1922209B CN 2005800056858 A CN2005800056858 A CN 2005800056858A CN 200580005685 A CN200580005685 A CN 200580005685A CN 1922209 B CN1922209 B CN 1922209B
Authority
CN
China
Prior art keywords
peptide
antibody
cell
amyloid beta
secretase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800056858A
Other languages
English (en)
Chinese (zh)
Other versions
CN1922209A (zh
Inventor
R·B·德马托斯
U·库希波特拉
H-C·杨
D·B·麦克鲁尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1922209A publication Critical patent/CN1922209A/zh
Application granted granted Critical
Publication of CN1922209B publication Critical patent/CN1922209B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
CN2005800056858A 2004-02-23 2005-02-17 抗Αβ抗体 Expired - Fee Related CN1922209B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54676404P 2004-02-23 2004-02-23
US60/546,764 2004-02-23
PCT/US2005/005198 WO2005082939A2 (en) 2004-02-23 2005-02-17 Anti-abeta antibody

Publications (2)

Publication Number Publication Date
CN1922209A CN1922209A (zh) 2007-02-28
CN1922209B true CN1922209B (zh) 2012-09-05

Family

ID=34910810

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800056858A Expired - Fee Related CN1922209B (zh) 2004-02-23 2005-02-17 抗Αβ抗体

Country Status (20)

Country Link
US (1) US20070190046A1 (cg-RX-API-DMAC7.html)
EP (1) EP1720909B1 (cg-RX-API-DMAC7.html)
JP (1) JP4851348B2 (cg-RX-API-DMAC7.html)
KR (2) KR100889430B1 (cg-RX-API-DMAC7.html)
CN (1) CN1922209B (cg-RX-API-DMAC7.html)
AT (1) ATE534667T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005217596B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0507856A (cg-RX-API-DMAC7.html)
CA (1) CA2556436C (cg-RX-API-DMAC7.html)
CY (1) CY1112162T1 (cg-RX-API-DMAC7.html)
DK (1) DK1720909T3 (cg-RX-API-DMAC7.html)
EA (1) EA009872B1 (cg-RX-API-DMAC7.html)
ES (1) ES2375627T3 (cg-RX-API-DMAC7.html)
IL (1) IL177611A (cg-RX-API-DMAC7.html)
NO (1) NO20064239L (cg-RX-API-DMAC7.html)
PL (1) PL1720909T3 (cg-RX-API-DMAC7.html)
PT (1) PT1720909E (cg-RX-API-DMAC7.html)
SI (1) SI1720909T1 (cg-RX-API-DMAC7.html)
UA (1) UA93181C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005082939A2 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
MX358175B (es) 2005-12-12 2018-08-08 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.
US7892544B2 (en) 2006-07-14 2011-02-22 Ac Immune Sa Humanized anti-beta-amyloid antibody
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
HUE034512T2 (en) 2007-01-05 2018-02-28 Univ Zuerich A method for providing disease-specific binding molecules and targets
WO2008084402A2 (en) 2007-01-11 2008-07-17 Philipps-Universitaet Marburg Diagnosis and treatment of alzheimer's and other neurodementing diseases
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
PT2238166E (pt) 2007-10-05 2014-02-11 Genentech Inc Utilização do anticorpo anti-amilóide beta em doenças oculares
RU2542967C2 (ru) * 2007-10-05 2015-02-27 Дженентек, Инк. Применение антитела против амилоида бета при глазных заболеваниях
EA201190025A1 (ru) 2008-11-25 2012-12-28 Байоджен Айдек Ма Инк. ПРИМЕНЕНИЕ АНТАГОНИСТОВ DR6 И p75 ДЛЯ ПРОМОТИРОВАНИЯ ВЫЖИВАНИЯ КЛЕТОК НЕРВНОЙ СИСТЕМЫ
BRPI0923157B1 (pt) 2008-12-19 2021-12-28 University Of Zürich Anticorpos anti-alfa-sinucleína e seus fragmentos, seus usos e método de preparação, composição compreendendo-os, bem como kit e métodos para o diagnóstico e monitoramento de uma doença sinucleinopática
WO2011060246A2 (en) 2009-11-12 2011-05-19 Genentech, Inc. A method of promoting dendritic spine density
CN102933601B (zh) 2010-04-15 2016-06-08 Abbvie公司 β淀粉样蛋白结合蛋白
MY164579A (en) 2010-07-30 2018-01-15 Ac Immune Sa Safe and functional humanized antibodies
PL3042917T3 (pl) * 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
PL2723379T3 (pl) 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
US20150209406A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
WO2014039781A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye & Ear Infirmary Treating hearing loss
JP6751344B2 (ja) 2013-09-13 2020-09-02 ジェネンテック， インコーポレイテッド 精製された組み換えポリペプチドを含む方法及び組成物
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
KR102362222B1 (ko) 2016-05-16 2022-02-11 더 제너럴 하스피탈 코포레이션 폐 상피 공학에서 인간 기도 줄기 세포
WO2018031334A1 (en) * 2016-08-11 2018-02-15 Eli Lilly And Company Aminothiazines and their use as bace1 inhibitors
AU2018321335B2 (en) 2017-08-22 2025-08-14 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
JP2025506411A (ja) 2022-02-03 2025-03-11 イーライ リリー アンド カンパニー アルツハイマー病の診断及び治療のための局所タウイメージング

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046237A2 (en) * 2000-12-06 2002-06-13 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT951466E (pt) 1996-12-23 2009-04-09 Lilly Co Eli Compostos cicloalquilo, lactama, lactona e relacionados, composições farmacêuticas compreendendo os mesmos, e métodos para a inibição da libertação do péptido β-amilóide e/ou da sua síntese pela utilização de tais compostos
US6518011B1 (en) * 1999-01-13 2003-02-11 Bristol-Myers Squibb Company Method for screening compounds to identify beta-amyloid production modulators
MXPA02008145A (es) * 2000-02-24 2004-04-05 Univ Washington Anticuerpos humanizados que secuestran al peptido beta amiloide.
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
ES2437875T3 (es) * 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046237A2 (en) * 2000-12-06 2002-06-13 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
同上.

Also Published As

Publication number Publication date
AU2005217596B2 (en) 2012-01-19
US20070190046A1 (en) 2007-08-16
KR20090005410A (ko) 2009-01-13
JP2008500279A (ja) 2008-01-10
SI1720909T1 (sl) 2012-01-31
ATE534667T1 (de) 2011-12-15
IL177611A (en) 2013-05-30
DK1720909T3 (da) 2012-01-30
CY1112162T1 (el) 2015-12-09
PL1720909T3 (pl) 2012-04-30
CA2556436C (en) 2014-04-01
EA009872B1 (ru) 2008-04-28
NO20064239L (no) 2006-11-20
EA200601545A1 (ru) 2007-02-27
PT1720909E (pt) 2011-12-23
BRPI0507856A (pt) 2007-07-10
JP4851348B2 (ja) 2012-01-11
KR100889430B1 (ko) 2009-03-23
ES2375627T3 (es) 2012-03-02
UA93181C2 (ru) 2011-01-25
IL177611A0 (en) 2006-12-10
AU2005217596A1 (en) 2005-09-09
KR20060126785A (ko) 2006-12-08
CN1922209A (zh) 2007-02-28
EP1720909A2 (en) 2006-11-15
EP1720909B1 (en) 2011-11-23
CA2556436A1 (en) 2005-09-09
WO2005082939A3 (en) 2005-10-27
WO2005082939A2 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
CN1922209B (zh) 抗Αβ抗体
US7927815B2 (en) Protein purification method
EA012162B1 (ru) Способ рефолдинга рекомбинантных антител
BR122020017346B1 (pt) Método de avaliação e de produção de uma molécula de ligação ao antígeno cuja atividade de ligação em um primeiro ph é maior do que aquela em um segundo ph
CN102712673A (zh) 用于纯化含fc的蛋白的色谱方法
US20130225796A1 (en) Protein purification method
JP2022521624A (ja) 抗ｃｄ４７抗体を含む製剤、その調製方法および使用
JP4812228B2 (ja) 抗体含有溶液の凝集物生成または白濁抑制方法
BR112021009544A2 (pt) Métodos para identificar ligações dissulfeto embaralhadas em um medicamento de proteína e de produção de um medicamento de proteína, e, composição farmacêutica
WO2017211313A1 (zh) 长效pcsk9特异性的结合蛋白及其应用
CN114213541B (zh) 一种全能核酸酶的单克隆抗体及其制备方法
JP2007006891A (ja) 免疫同等性のためのインビボモデル
CN117327177B (zh) 抗脂联素抗体、检测脂联素的试剂和试剂盒
CN117659201B (zh) 抗可卡因抗体或其功能性片段、检测可卡因的试剂和试剂盒
CN118440195B (zh) 抗脂联素抗体、检测脂联素的试剂和试剂盒
WO2025118871A1 (zh) 一种抗bdca-2抗体及其制备方法和应用
CN121159706A (zh) 一种抗人IgM的抗体及其应用
CN104804083B (zh) 一种鼠源单克隆抗体及其制备方法和用途
CN118324923A (zh) 一种特异性结合维生素k3的抗原结合蛋白及其应用
CN104829724B (zh) 一种鼠源单克隆抗体及其制备方法和用途
JPS60258128A (ja) ラツトモノクロ−ナル抗体
CN118146377A (zh) 靶向pear1受体的抗血小板聚集的抗体及其制备方法和应用
CN114790245A (zh) 一种抗体及其用途
MXPA06009560A (en) Anti-abeta antibody
EA042982B1 (ru) Моноклональные антитела против участка бета-цепи trbv9 человека

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120905

Termination date: 20160217

CF01 Termination of patent right due to non-payment of annual fee